Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 29,275 call options on the company. This represents an increase of approximately 43% compared to the average volume of 20,478 call options.

Recursion Pharmaceuticals Stock Up 4.3%

RXRX traded up $0.23 on Wednesday, hitting $5.59. 34,337,002 shares of the company were exchanged, compared to its average volume of 16,395,603. Recursion Pharmaceuticals has a twelve month low of $3.79 and a twelve month high of $12.36. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -3.16 and a beta of 0.91. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $4.82 and a two-hundred day moving average price of $6.09.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. On average, equities analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $36,000. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after purchasing an additional 2,026 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after purchasing an additional 2,387 shares during the last quarter. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $54,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on RXRX. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday. Morgan Stanley assumed coverage on Recursion Pharmaceuticals in a report on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective on the stock. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.